DP1

ACTX Announces New Line of "GrowPod" Controlled Environment Farms

Retrieved on: 
Thursday, February 2, 2023
ENTRY, Restaurant, UNIT, Nutrient film technique, Farmer, NSF, Ticker, Water, GROW, Plant, Carbon, HVAC, Food, DP1, MAX, Pesticide, Filtration, Environment, NFT, FLEX, Aquaculture, Agriculture

CORONA, Calif., Feb. 2, 2023 /PRNewswire/ -- Advanced Container Technologies, Inc (Ticker: ACTX), announced a new line of GrowPod Controlled Environment Farms to accommodate a wide range of customers and specialty plant cultivations. ACTX is the exclusive distributor of these systems, which were all designed and built by GP Solutions.

Key Points: 
  • Also known as vertical farms, grow rooms, and container farms, these automated modular systems provide a clean environment so that plants can reach their full potential
    CORONA, Calif., Feb. 2, 2023 /PRNewswire/ -- Advanced Container Technologies, Inc (Ticker: ACTX), announced a new line of GrowPod Controlled Environment Farms to accommodate a wide range of customers and specialty plant cultivations.
  • ACTX is the exclusive distributor of these systems, which were all designed and built by GP Solutions .
  • Additionally, the entire line of pods are modular and stackable allowing for multi-pod farms and large commercial enterprises.
  • Also known as vertical farming, grow rooms, and container farms, GrowPods provide a clean environment so that food and plants can reach their full potential.

Wintermar Offshore (WINS:JK) Acquires 2 Additional AHTS and Celebrates the 12th Anniversary of Listing on IDX

Retrieved on: 
Wednesday, November 30, 2022
Platform supply vessel, Growth, Quality, Stanza, Environment, DP2, OSV, WINS, Occupational safety and health, ISO 9001:2015, Asset integrity management systems, IDX, DP1, AHTS, ISO, ABS, PSV, IPO

The two AHTS will be delivered by December 2022, are ABS classed and have DP1 and FiFi1 capability, and expected to be utilized from 1Q2023.

Key Points: 
  • The two AHTS will be delivered by December 2022, are ABS classed and have DP1 and FiFi1 capability, and expected to be utilized from 1Q2023.
  • With this latest purchase, Wintermar's fleet will be increased the fleet to 41 Vessels by end December 2022.
  • Today also marks the Company's 12th IPO anniversary, as Wintermar's shares were first listed on the IDX on November 29, 2010.
  • All vessels are operated by experienced Indonesian crew, tracked by satellite systems and monitored in real-time by shore-based Vessel Teams.

Hippo’s First Connect Simplifies Agent Onboarding with New Carrier Store and Adds Pacific Specialty Insurance

Retrieved on: 
Thursday, November 17, 2022
Residential Building & Real Estate, Construction & Property, Professional Services, Insurance, Acosta Sales & Marketing, DP1, Multimedia, NYSE, Insurance, Small business, Life, Airline

"The new Carrier Store streamlines the tedious onboarding process for new agents, and helps existing First Connect agents discover new carrier options and start quoting select carrier offerings within minutes, First Connect President Aviad Pinkovezky.

Key Points: 
  • "The new Carrier Store streamlines the tedious onboarding process for new agents, and helps existing First Connect agents discover new carrier options and start quoting select carrier offerings within minutes, First Connect President Aviad Pinkovezky.
  • The new store allows First Connect carriers to quickly grow their agent footprint by targeting agents that meet specific criteria such as location.
  • Hippo Holdings Inc.s (NYSE: HIPO) operating subsidiaries include Hippo Insurance Services, Hippo Home Care, First Connect Insurance Services, Spinnaker Insurance Company, Spinnaker Specialty Insurance Company, and Mainsail Insurance Company.
  • First Connect Insurance Services is a licensed property casualty insurance agent with products underwritten by various insurance companies.

Pathway Deep in the Brain Makes It Resilient after Injury

Retrieved on: 
Wednesday, July 6, 2022
Cell, The Pew Charitable Trusts, Mouse, Iran National Science Foundation, Department, University of California, San Francisco, Brain, National Institute of Neurological Disorders and Stroke, Astrocyte, Thalamus, Research, National Institute, Attention, DP2, National Science Foundation, Nutrient, Multimedia, University of Amsterdam, Disease, Seizure, Department of Defense Serum Repository, Mortality, F31, R01, UCSF, Innovation, SAN, Risk, National Cancer Institute, University, Technology, National Institute of Mental Health, Doctor of Philosophy, Neuron, Mental health, DP1, Science Translational Medicine, Gladstone Institutes, Animal, Human, National, Time, Lists of diseases, P30, Injury, MD, UCLA, Mobile phone, Medical imaging, Aroma compound, Trapping, Pharmaceutical industry, Stroke, William Ewart Gladstone

SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- For days, and even years, after someone suffers a stroke or traumatic brain injury, they have an increased risk of developing epilepsy. Now, researchers at Gladstone Institutes discovered that star-shaped cells called astrocytes in the thalamus play a key role in making mice with brain injuries susceptible to seizures.

Key Points: 
  • The team also analyzed human post-mortem brain tissue and showed that the same cells identified in mice might be altered in the thalamus of people affected by brain injury and stroke.
  • The findings, published in the journal Science Translational Medicine, suggest that targeting a protein in these cells could prevent the long-term damage that follows brain injury.
  • At the time of a stroke or traumatic brain injury, many cells at the site of the injury die almost immediately.
  • Previous studies from the team have shown, in rodent models, that activation of astrocytes in the thalamus is a common consequence of brain injury.

Offshore Supply Vessel Maritime Transport Specialist Guice Offshore Expands Fleet

Retrieved on: 
Tuesday, April 26, 2022
Energy, Maritime, Logistics, Supply Chain Management, Transport, Other Energy, Government, Google Guice, Exploration, Caterpillar, Software, Crusader, Research, Operation, Science, Compliance, GO, DP1, U.S. Coast Guard environmental protection, Maintenance, DP2, Five Go Adventuring Again, Wind, Multimedia, A-frame, Shipbuilding, Dredging, Oil, SpaceX fairing recovery program

View the full release here: https://www.businesswire.com/news/home/20220426005193/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220426005193/en/
    Guice Offshore's newest platform supply vessel GO Crusader was recently in Jacksonville, Florida preparing for her next mission.
  • These and all Guice Offshore vessels have undergone significant technical, structural and/or equipment enhancements to meet the most demanding customer requirements, Guice Offshore principal Billy Guice noted.
  • Headquartered in Madisonville, Louisiana with Operations offices in Lafayette, Louisiana and Cape Canaveral, Florida, Guice Offshore operates a 10-vessel fleet of U.S.
  • Guice Offshore operates from coast to coast in North America and select international locales.

Nature Paper: BioAge’s Oral Drug Targeting the Aging Immune System Prevents Death From COVID-19 in Aged Mice

Retrieved on: 
Monday, March 21, 2022
Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Infectious Diseases, Clinical Trials, Human, Shionogi, DP1, Death, Mortality, Nature, Mouse, EUA, Biotechnology, Doctor of Philosophy, B cell, Degenerative disease, PGD2, Ageing, CEO, Severe acute respiratory syndrome coronavirus 2, Immunity, Immunology, MD, Inflammation, COVID-19, Disease, Infection, RSV, Urinary tract infection, Animal, Allergic rhinitis, University, Patient, Kaiser Permanente, Vaccine, Pharmaceutical industry, Microbiology

In the study, daily doses of BGE-175 prevented death in aged mice infected with a lethal dose of SARS-CoV-2.

Key Points: 
  • In the study, daily doses of BGE-175 prevented death in aged mice infected with a lethal dose of SARS-CoV-2.
  • Ninety percent of mice that received the drug survived, whereas all untreated control mice died.
  • Unlike antivirals currently being investigated to treat COVID-19, BGE-175 corrects these age-related immune deficits rather than targeting the infecting pathogen.
  • The drug acts by inhibiting the PGD2 DP1 protein, which BioAges AI-based, human-centric discovery platform has identified as a key target for immune aging.

BioAge Appoints Rekha Hemrajani and Jason Coloma to its Board of Directors

Retrieved on: 
Thursday, August 19, 2021
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Dartmouth, University, Kaiser Permanente, Health, CFO, Senior, Sarcopenia, Therapy, Credit Suisse First Boston, Business, Lehman Brothers, Biology, Degenerative disease, Mergers and acquisitions, CEO, PGD2, Computer science, Exelixis, Doctor of Philosophy, Roche, Northwestern University, Translation, Frailty, Onyx Pharmaceuticals, Biotechnology, MBA, COO, VP, Drug development, Tuck School of Business, Ageing, Muscle atrophy, Immune system, CBO, University of California, Berkeley, St. Anthony Foundation, Credit Suisse, DP1, Third Rock Ventures, HIF, COVID-19, Muscle weakness, Pharmaceutical industry, Management, Medicine

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Rekha Hemrajani and Jason Coloma to the companys board of directors.

Key Points: 
  • BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Rekha Hemrajani and Jason Coloma to the companys board of directors.
  • We are thrilled to welcome Jason Coloma and Rekha Hemrajani to BioAges board of directors, said Kristen Fortney, CEO of BioAge Labs.
  • Jason Coloma, MBA, Ph.D., is CEO of Maze Therapeutics, Inc. a biotech company focused on translating genetic insights into clinical innovations.
  • Rekha Hemrajani, MBA, is a senior executive with more than 20 years of biopharmaceutical industry experience.